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Abstract 
Purpose: To enhance the solubility and dissolution rate of the antidiabetic drug repaglinide by solid 
dispersion (SD) technique 
Method: The solid dispersion of repaglinide was prepared by solvent evaporation method using the 
hydrophilic carrier, polyethylene glycol 4000 (PEG 4000) in three drug:PEG 4000 ratios (1:1, 1:3, 1:5). 
For comparison, physical mixtures of repaglinide and PEG 4000 in the same ratios were also prepared. 
The formulations were characterized by Fourier transformed infrared spectroscopy (FTIR), x-ray 
diffractometry (XRD) and differential scanning colorimetry (DSC). Phase solubility study of pure 
repaglinide, physical mixture and solid dispersion was performed in distilled water. Dissolution studies 
were carried out in pH 7.4 phosphate buffer. 
Results: DSC and XRD results indicate that repaglinide exists in amorphous form in solid dispersion. 
FT-IR analysis demonstrated the presence of intermolecular hydrogen bonding between repaglinide and 
PEG 4000 in the solid dispersion. The solubility of pure repaglinide was enhanced from 22.5± 5.0 to 
235.5± 5.0 µg/mL in distilled water at 37 0C. Rapid burst release (80 - 86 %) from the solid dispersion 
formulations was observed within 15 min. 
Conclusion: The solubility and dissolution rate of repaglinide are enhanced by formulating SDs of 
repaglinide with PEG 4000. This will likely lead to increase in bioavailability which would be beneficial 
for better glucose control in diabetic patients. 
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The oral bioavailability of a pharmaceutically 
active ingredient depends on its water solubility 
and dissolution rate. Rate of dissolution is the 
rate determining step for the onset of therapeutic 
activity [1].Water insoluble drugs are usually 
characterized by a low bioavailability due to less 
absorption which is a major concern of 
pharmaceutical industries worldwide 
[2].Micronization, co-crystal formation, 
cyclodextrin complexation, salt formation, use of 
surface active agents, co-solvency are some of 
the approaches to improve the dissolution rate of 
the drugs [3]. Solid dispersion (SD) is one of the 
most widely used techniques to improve solubility 
as well as dissolution rate of poorly water soluble 
drugs. This method involves a dispersion of one 
or more active ingredients in an inner carrier or 
matrix in solid state prepared by melting, 
dissolution in solvent or melting solvent method 
[4]. 
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SD is generally prepared by solvent method or 
fusion method. In solvent method, the drug and 
carrier are dissolved in a mutual organic solvent 
followed by solvent evaporation, whereas in 
fusion method, drug-carrier mixtures are 
prepared by co-melting and cooling. In both 
methods, a suitable carrier needs to be selected 
in order to achieve enhanced solubility [5]. 
Hydrophilic synthetic polymers have been widely 
investigated as carrier substances for solid 
dispersions. Polyethylene glycol (PEG) and 
polyvinylpyrrolidone (PVP) are amongst the most 
frequently investigated hydrophilic polymeric 
carriers.SD using suitable carrier, changes the 
micro-environment of the drug particles, reduces 
the drug particle size thereby increasing 
dissolution, solubility and thus changes 
biopharmaceutical properties [6]. 
 
Repaglinide is an antidiabetic drug in the class of 
medications known as meglitinides, and was 
invented in 1983. Repaglinide lowers blood 
glucose by stimulating the release of insulin from 
the pancreas. It achieves this by closing ATP-
dependent potassium channels in the membrane 
of the beta cells. This depolarizes the beta cells, 
opening the cells' calcium channels, and the 
resulting calcium influx induces insulin secretion. 
Repaglinide is a poorly water-soluble compound, 
with water solubility of approximately 20 μg/mL, 
high lipophilicity (logP = 3.97) and relatively low 
oral bioavailability (56 %) which is attributed to 
poor dissolution (BCS class II) and it undergoes 
hepatic first pass metabolism [7-9]. 
 
The aim of the present study was to prepare and 
characterize solid dispersion of repaglinide so as 
to improve its dissolution property and 
bioavailability. Solubility and dissolution tests 
were carried out to evaluate the effectiveness of 




Repaglinide was received as a gift from Zhejiang 
Haixiang Pharmaceutical Co., Ltd. (Zhejiang, 
China) while PEG 4000 was received from 
Clariant (Germany). Double distilled water was 
used throughout the study and all the other 
chemicals used were of analytical grade. 
 
Preparation of SD by solvent evaporation 
method 
 
SD of RPG was prepared in PEG 4000 by 
solvent evaporation method [10]. For solvent 
evaporation method, RPG was dissolved in 
sufficient quantity of acetone; to this solution an 
appropriate amount of PEG 4000 was added. 
The SDs of RPG in PEG 4000 in three different 
weight ratios (1:1, 1:3, 1:5) were prepared. The 
solvent was evaporated under reduced pressure 
at 45 °C by using rotary evaporator and the 
resulting residue dried under vacuum for 4 h. The 
mixture was stored overnight in a desiccator. The 
hardened mixture was powdered in a mortar, 
sieved through a 100- mesh screen (149 µ), and 
stored in a screw-cap vial at room temperature 
until further use. 
 
Physical mixtures were prepared by mixing RPG 
with PEG 4000 at the same weight ratios (1:1, 
1:3, 1:5) in a mortar until a homogeneous mixture 
was obtained. The physical mixtures were 
passed through a 100 mess sieve and stored in a 
screw-cap vial at room temperature until further 
use. 
 
Phase solubility study 
 
Excess amount of pure RPG, solid dispersion 
containing RPG and physical mixtures was 
added to 5 mL of distilled water in screw cap 
vials to ensure the drug reached saturation level. 
These solutions were mechanically shaken for 24 
h at 37 oC and then the solutions were 
centrifuged at 15,000 rpm for 3 min [11]. The 
saturated solutions were then diluted to proper 
concentration and absorbance was measured at 





The SD and physical mixture equivalent to 15 mg 
of RPG were weighed and added into the 
dissolution medium (pH 7.4 phosphate buffer, 
900 ml) maintained at 37 ± 0.5 oC. At the 
specified times 5 mL samples were withdrawn by 
using syringe filter and then assayed for RPG 
content by measuring the absorbance at 247.5 
nm using a UV-Visible spectrophotometer (UV-
1800, Shimadzu, Japan). Dissolution studies 





FT-IR spectra were obtained by an FT-IR 
spectrophotometer (Bruker, Germany) using the 
potassium bromide (KBr) disk method. Data were 
collected over a spectral region from 4000 to 400 
cm-1 with a resolution of 2 cm-1. 
 
Differential scanning calorimetry (DSC) 
 
The DSC measurements were performed on a 
DSC-6100 differential scanning calorimeter with 
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a thermal analyzer (Seiko Instruments, Japan). 
All accurately weighed samples were placed in 
sealed aluminum pans, before heating under 
nitrogen flow (20 mL/min) at a scanning rate of 
10 °C min−1 from 25 to 250 °C. An empty 




XRD measurement was carried out using a 
powder x-ray diffractometer (Thermo Scientific, 
Waltham, Massachusetts, USA) with Ni-filtered 
Cu Kα radiation, a tube voltage of 40 kV and a 
tube current of 40 mA. The scanning rate was 10 





DSC thermograms of RPG, PEG 4000, physical 
mixture of RPG with PEG 4000, and solid 
dispersion are shown in Figure 1.  Pure RPG and 
its physical mixture with PEG 4000 exhibited an 
endothermic peak at around 135 °C, which was 
consistent with the melting point of repaglinide. 
The small peak in physical mixture might be 
explained by the dilution effect of PEG 4000. 
However, no such peaks were observed in the 
PEG 4000 and solid dispersion group. The 
former resulted from the amorphous nature of the 
polymer, and the later revealed no crystallinity of 
repaglinide existed in solid dispersion, indicating 
that repaglinide might be in an amorphous form. 
 
Figure 2 shows the FT-IR spectra of pure RPG 
(A), PEG 4000 (B), physical mixture containing 
RPG + PEG 4000 (C) and solid dispersion (D). 
Characteristic absorption bands of pure RPG (A) 
were observed at 3310, 1570, 1085, 915 and 
783 cm−1.  These absorption bands also existed 
at the FT-IR spectrum of physical mixture (C), 
revealing that there was no interaction between 
RPG and PEG 4000 in the physical mixture. In 
contrast, the absorption band attributed to O–H 
stretching vibration of repaglinide disappeared in 
the FT-IR spectrum of solid dispersion (D). It 
might be the result of the formation of hydrogen 









Figure 2: FT-IR spectra of pure RPG (A), PEG 4000 (B), physical mixture containing RPG + PEG 4000 (C) and 
solid dispersion (D) 
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           Figure 3: Diffractogram of pure RPG (A), PEG 4000 (B) and SD of RPG (C) 
 
Figure 3 shows the diffractogram of pure RPG 
(A), PEG 4000 (B) and SD of RPG (C). RPG 
showed the characteristic intense peaks at 2θ of 
20, 30, 33, 44 and 56.50. These peaks clearly 
indicated crystalline nature of the pure RPG. 
Also, the characteristic intense peaks for PEG 
4000 were observed at 2θ of 22.5, 29 and 37.50. 
The intensity of these peaks from RPG and PEG 
4000 disappeared in diffractogram of the SD as 
observed in C. This pattern indicates the 
amorphous nature of RPG in SD. 
 
Phase solubility  
 
RPG belongs to the BCS class II drug, i.e., low 
soluble and high permeable in nature. As 
discussed before it is a poorly water soluble drug 
having log p value of 3.97.The intrinsic aqueous 
solubility of pure RPG was determined and it was 
found to be to be 22.5 ± 5 µg/mL. This intrinsic 
solubility of the pure RPG was found to be 
equivalent to reported solubility in previously 
published literature [12]. 
 




Pure RPG 22.5± 5.0 
RPG: PEG 4000 (1:1) 28.3± 5.0 
RPG: PEG 4000 (1:3) 35.5± 5.0 
RPG: PEG 4000 (1:5) 42.8± 5.0 
SD of RPG: PEG 4000 (1:1) 62.5± 5.0 
SD of RPG: PEG 4000 (1:3) 155.8± 5.0 
SD of RPG: PEG 4000 (1:5) 235.5± 5 
 
So to enhance the aqueous solubility of RPG, 
physical mixture with hydrophilic carrier PEG 
4000 and SD were prepared. It can be found that 
the solubility was enhanced in all physical 
mixtures and SD’s.  The solubility of RPG was 
increased by increasing the concentration of the 
hydrophilic carrier in both physical mixture and 
SD. In case of physical mixture, maximum 
solubility of 42.8 ± 5 was found. Very promising 
results were obtained in case of the SD. The 
solubility was enhanced from 22.5 ± 5 to 235.5 ± 
5 µg/mL, i.e., ~ 10 times solubility was enhanced 
when RPG was converted to the SD. The 
solubility data are presented in Table 1. 
 
In vitro dissolution 
 
Dissolution study of pure RPG, physical mixtures 
and SD was performed in pH 7.4 phosphate 
buffer. Figure 6 shows the dissolution profiles of 
repaglinide, its physical mixture and solid 
dispersion with PEG 4000. These three 
formulations exhibited wide difference in 
dissolution pattern. The fastest one was solid 
dispersion, followed by the physical mixture 
followed by pure RPG. The rapid burst release 
(80 -86 %) was observed within 15 min in case of 
SD formulations. It clearly indicated the ideal 
complexation between the RPG and PEG 4000. 
The possible reason for the enhancement of the 
drug release from SD was the reduction in 
crystalline nature of pure of RPG and conversion 
in to the more soluble amorphous nature. The 
reduction in particle size as well as enhancement 
of the wettability of the drug may also be the 
probable reason for the enhancement of the drug 
release. The drug release pattern of the physical 
mixture found to be the lower as compare to the 
SD. This was due to the existence of the drug in 
crystalline form that led to more energy to break 
up the crystal structure. So it was clear that the 
SD technique was vital tool for the enhancement 
of the solubility as well as the dissolution profile 
of poorly water soluble drug [13]. 
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Increased wettability, alteration of surface 
properties of drug particle, formation of 
amorphous complex, solubilization effect of PEG 
4000, reduction of particle aggregation of the 
drug, might be responsible for the enhanced 
solubility and dissolution rate of RPGL from its 
SD and to some extent in PMs. The solubility of 
RPG was increased by increasing the 
concentration of the hydrophilic carrier in both 
physical mixture and SD. The fastest dissolution 
rate was found for solid dispersion, followed by 
the physical mixture followed by pure RPG. The 
rapid burst release (80-86 %) was observed 
within 15 min in case of SD formulations. From 
FTIR spectroscopy, it was concluded that there 
was no well-defined chemical interaction 
between RPGL and PEG 4000 in SDs and in 
physical mixture. No endothermic peak of RPGL 
was present in the DSC thermograms of SDs 
with PEG 4000 suggesting the absence of 
crystalline RPGL, however, the XRD studies 
indicated the complete amorphous nature of the 




The solubility and dissolution rate of RPG can be 
enhanced by formulating SDs of RPG with PEG 
4000. Enhancement of solubility and dissolution 
rate will likely increase bioavailability which 
would be beneficial for better glucose control in 
diabetic patients. However, in vivo studies are 
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